Sangamo Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2017 | — | $187.9M | $49.8M |
| FY2018 | — | $366.5M | $140.4M |
| FY2019 | — | $432.6M | $80.4M |
| FY2020 | — | $498.2M | $131.3M |
| FY2021 | — | $375.3M | $178.9M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2017 | — | $187.9M | $49.8M |
| FY2018 | — | $366.5M | $140.4M |
| FY2019 | — | $432.6M | $80.4M |
| FY2020 | — | $498.2M | $131.3M |
| FY2021 | — | $375.3M | $178.9M |